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The cytokines interleukin (IL)-1b and tumor necrosis factor (TNF)-a induce b-cell death in type 1 dia-
betes via NF-jB activation. IL-1b induces a more marked NF-jB activation than TNF-a, with higher
expression of genes involved in b-cell dysfunction and death. We show here a differential usage of
the IKK complex by IL-1b and TNF-a in b-cells. While TNF-a uses IKK complexes containing both
IKKa and IKKb, IL-1b induces complexes with IKKa only; this effect is achieved by induction of IKKb
degradation via the proteasome. Both IKKc and activation of the TRAF6-TAK1-JNK pathway are
involved in IL-1b-induced IKKb degradation.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Type 1 Diabetes mellitus (T1D) is an autoimmune disease
characterized by a selective destruction of the insulin producing
b-cells [1]. During the inﬂammatory process known as insulitis,
pro-inﬂammatory cytokines such as interleukin (IL)-1b, tumor
necrosis factor (TNF)-a and interferon (IFN)-c are secreted by im-
mune cells invading the islets and contribute for b-cell dysfunction
and apoptosis [1]. Activation of the transcription factor NF-jB is
necessary for cytokine-induced b-cell dead [2–6], which is surpris-
ing, since in other cell types NF-jB activation has mostly an anti-
apoptotic role [7,8]. This key transcription factor controls, directly
or indirectly (mainly via NO production), the expression of several
genes and transcription factors in b-cells. These genes are involved
in the regulation of survival/apoptosis, function and immune
system cells attraction [9–11].chemical Societies. Published by E
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tis).NF-jB is composed by a family of ﬁve members that can form
homo or heterodimers, depending on the cell type and stimulus
[12–14]. These dimers are normally kept inactive in the cytoplasm
by their binding to the inhibitory jB (IjB) proteins [14]. Binding of
IL-1b or TNF-a to their speciﬁc receptors recruits scaffold proteins
and activates a cascade of kinases and ligases leading to the IjB
kinase (IKK) complex activation. This complex induces IjB phos-
phorylation leading to its degradation, allowing NF-jB transloca-
tion to the nucleus [14]. NF-jB transcriptional activity can be
also regulated by post-translational mechanisms such as phos-
phorylation of the p65 subunit by the mitogen-activated protein
kinases (MAPKs), IKK complex, AKT (or protein kinase B) and oth-
ers [14,15]. Many NF-jB-activating signalling cascades converge to
the IKK complex whose activation therefore has a key role in cell
biology [16,17]. This complex is formed by three proteins: IKKa,
IKKb and IKKc (NEMO) [14,17]. The kinase subunits IKKa and IKKb
share a similar structural identity, including a N-terminal catalytic
domain, a central dimerization leucine zipper and a C-terminal
helice-loop-helice domain [14,17]. They are associated as homo-
or heterodimer to the regulatory IKKc subunit [14,17]. In spite of
their high similarity, IKKa and IKKb differ on their function and
activation depending on the type of stimulus [18–21].
Due to its pro-apoptotic and inﬂammatory effects, it is impor-
tant to better understand the speciﬁc characteristics of NF-jB acti-
vation in b-cells. We have previously shown that cytokine-inducedlsevier B.V. All rights reserved.
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sity and duration [7]. Furthermore, IL-1b induced NF-jB activation
has a more important pro-apoptotic effect than TNF-a [5,7]. This
seems to be related to the stronger intensity of NF-jB induction
by IL-1b and of preferential activation of kinases that modulate
NF-jB and other genes, including the IKK complex and ERK [5,7].
In order to unravel the signal transduction involved in these differ-
ences, we presently studied the speciﬁc characteristics of IKK
activation by IL-1b or TNF-a in b-cells.
2. Materials and methods
2.1. Cell culture and treatment
Insulin-producing INS-1E cells [22], a kind gift from Prof. C.
Wolheim (Centre Médical Universitaire, Geneva, Switzerland),
and rat ﬁbroblasts 208F cells [European Collection Cell Cultures
(ECACC), Salisbury, UK] were cultured as previously described
[7]. Key ﬁndings were conﬁrmed in primary FACS-puriﬁed rat
b-cells, isolated as previously described [23,24]. Adult Wistar rats
(Charles River Laboratories Belgium, Brussels, Belgium) were
housed and used according to the guidelines of the Belgian Regula-
tions for Animal Care; the Ethical Committee for Animal Experi-
ments of the ULB approved the experimental protocol. Cells were
exposed to recombinant human IL-1b (100 U/ml, a kind gift from
Dr. C.W. Reinolds, National Cancer Institute, Bethesda, MD-USA)
or recombinant murine TNF-a (1000U/ml, Innogenetics, Gent-Bel-
gium); these concentrations were selected based on previous
dose–response experiments [11,25]. The IKK inhibitors BMS-
345541 (Sigma) (15–100 lM), inhibitor IV (Calbiochem) (25 lM)
and JNK inhibitor SP600125 (Sigma) (10 lM) were used prior
(2–3 h) to cytokine treatment.
2.2. Immunoﬂuorescence
Cells were plated in poly-lysine coated cover-slips, and after
treatment ﬁxed with 4% paraformaldehyde and permeabilized
with 70% acetone +30% methanol. Incubation with anti-p65 (Santa
Cruz Biotechnology, Santa Cruz, CA-USA) or anti-hemaglutinin
(HA) (Roche Diagnostics, Mannheim-Germany) and secondary
antibody anti-rabbit IgG conjugated with FITC (Jackson Immuno-
Research, Westgrove, PA-USA) done as previously described [5].
2.3. RNA interference
Small interfering RNA (siRNA) against IKKa, IKKb, IKKc, TRAF6
and TAK1 Silencer Select Pre-designed siRNA (Ambion, Austin –
TX, USA) and Stealth RNAi™ siRNA (Invitrogen, Carlsbad – CA,
USA) were used to knock down expression of respective genes.
Allstars Negative Control siRNA (Qiagen, Venlo, Netherlands) was
used as a negative control. siRNA transfection was done as previ-
ously described [26].
2.4. Western blot assay
Total or immunoprecipitated protein extracts were obtained
from cells after exposure to treatment and/or transfection with
speciﬁc siRNA [5,7]. Proteins were fractioned in a 10% SDS–PAGE
and transferred to a nitrocellulose membrane. Immunoblot analy-
sis was performed with anti-IKKa, IKK-b, IKKc, P-IjBa (Santa Cruz,
Biotechnology, Santa Cruz – CA, USA), TRAF6, TAK1, total JNK,
P-JNK, anti-polyubiquitin and anti-a-tubulin (Cell Signaling,
Beverly, MA) antibodies, followed by incubation with a secondary
horseradish peroxidase-labeled anti-IgG (Santa Cruz Biotechnology
or Cell Signaling). The quantiﬁcation of the speciﬁc bands was doneby the Scion Image (Scion Corporation, Frederick, MD). Values were
corrected by values obtained for a-tubulin (housekeeping protein).
2.5. IKK kinase assay
Protein extracts were obtained as described [5]. An equal
amount of protein was incubated for 2 h at 4 C with either anti-
IKKc (Santa Cruz Biotechnology) or anti-HA (Roche Diagnostics,
Mannheim-Germany; negative control), followed by 2 h incubation
with protein A-sepharose™CL-4B beads (GE Healthcare, Uppsala;
Sweden). Beads were washed and incubated at 30 C in kinase
buffer with GST-IjBa recombinant protein and 5 mM ATP [5].
Western blot was performed as described above.
3. Results
3.1. Differential usage of IKK complex subunits by IL-1b and TNF-a in
pancreatic b-cells
To prevent NF-jB activation in b-cells we used an IKK inhibitor
(BMS-345541 – BMS) with speciﬁcity for IKKb containing IKK com-
plexes [27]. Pre-treatment with BMS inhibited TNF-a-induced NF-
jBactivation (’80%) asmeasuredbyp65 (NF-jB subunit)migration
to the nucleus in INS-1E cells (Fig. 1A and Supplementary Fig. 1S A)
and primary rat b-cells (Fig. 1B). BMS, however, did not prevent IL-
1b-induced NF-jB activation (Fig. 1A, B and Supplementary Fig. 1S
A). An IKK activation assay conﬁrmed that BMS inhibits TNF-a- but
not IL-1b-induced NF-jB activation (Fig. 1C). Subsequent experi-
ments indicated that BMS failure to prevent IL-1b-induced NF-jB
activation was observed at different IL-1b concentrations (from 5
to 100 U/ml) (Supplementary Fig. 2S A), BMS concentrations (40–
80 lM) or time of pre-treatment (from 3 to 16 h) (Supplementary
Fig. 2S B). The use of another IKK inhibitor targeting IKKb containing
IKK complexes (inhibitor IV), showed again a higher efﬁciency
against TNF-a than IL-1b (Supplementary Fig. 1S B and C).
3.2. IL-1b induces IKKb degradation in pancreatic b-cells
We next analyzed the composition of the IKK complex in INS-1E
cells after exposure to IL-1b or TNF-a for 10–90 min, since NF-jB
activation by these cytokines starts between 10–30 min [5,7].
Analysis of the IKK complex showed that IL-1b, but not TNF-a in-
duced IKKb disappearance without changing IKKa expression
(Fig. 2A). Neither IL-1b nor TNF-a modiﬁed IKKa or IKKb levels in
rat ﬁbroblast cells (208F) (Supplementary Fig. 3S A), suggesting a
preferential effect on b-cells.
IL-1b-induced IKKb degradation was already observed after
10 min and lasted up to 2 h (Fig. 2B and Supplementary Fig. 3S
B). On the other hand, TNF-a did not trigger IKKb degradation at
any of the time points studied (Supplementary Fig. 3S B). IL-1b-in-
duced IKKb degradation was conﬁrmed in FACS-puriﬁed b-cells
(Supplementary Fig. 3S C). IKKb degradation is dependent on pro-
teasome activity, since MG132 (a proteasome activity blocker) pre-
vented it (Fig. 2C).
3.3. IL-1b induced IKKb degradation relies on IKKc
The use of speciﬁc siRNAs against the components of the IKK
complex (a, b and c) indicated that IL-1b does not induce IKKb deg-
radation following knock down (KD) of IKKc (Fig. 3). On the other
hand, IKKa KD did not prevent IL-1b induced IKKb degradation
(Fig. 3). The speciﬁcity of each siRNA was conﬁrmed by its ability
to KD only the speciﬁc IKK targeted (Fig. 3A and Supplementary
Fig. 4S). Use of a second set of siRNAs against these three subunits
conﬁrmed the observations described above (data not shown).
Fig. 1. BMS-345541 inhibits TNF-a- but not IL-1b-induced IKK activation. (A–B): analysis of IL-1b or TNF-a-induced NF-jB (p65 subunit) nuclear localization in INS-1E cells
(A) and rat primary b-cells (B) in the presence (grey bars) or absence (white bars) of 3 h pre-treatment with IKK inhibitor BMS-245541 (BMS, 50 lM). Cells were exposed to IL-
1b (IL), TNF-a (TNF) or left untreated (control) for 30 min. Results are the mean ± SEM of 4 independent experiments. ⁄P < 0.05 BMS treated cells vs. respective controls; paired
t-test. (C): IKK activity assay; INS-1E cells were pre-treated as described in A–B with 25 or 50 lM of BMS and then exposed to IL-1b, TNFa or left untreated (control) for
30 min. Cells were lysed and the IKK complex was immunoprecipitated (IP) with anti-IKKc antibody. IKK activation was measured by its capacity to phosphorylate the
substrate glutathione-S-transferase (GST)-IjBa. Western blot for IKKa showed similar IP of the IKK complex. Anti-haemagglutinin (HA) antibody was used as a negative
control for IP. The ﬁgure is representative of three similar experiments.
Fig. 2. IL-1b, but not TNF-a, induces IKKb degradation in b-cells. (A–B): INS-1E cells exposed to IL-1b (IL) or TNF-a (TNF) or left untreated (control) for the time indicated in
the ﬁgure. (A): cells were lysed and the IKK complex was immunoprecipitated (IP) with anti-IKKc antibody and Western blot for IKKa and IKKb performed as described in
Methods. Anti-haemagglutinin (HA) antibody was used as a negative control for IP. (B): the protein cell lysate was directly used in Western blot assays for IKKa and IKKb;
tubulin was analyzed to conﬁrm similar protein loading. (C): INS-1E cells were pre-treated or not with the proteasome inhibitor MG132 (2 lM) for 2 h, and then exposed to
IL-1b (IL) or TNF-a (TNF) or left untreated (control) for 15 min. Cells were lysed and used in Western blot assay for IKKa and IKKb; tubulin was used to conﬁrm similar protein
loading. Figures shown are representative of three to four experiments.
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dependent signalling pathway
We next investigated the role of TNF receptor associated factor
(TRAF)-6, an adaptor protein involved in IL-1b- but not TNF-a-in-
duced NF-jB activation [14,28] in IKKb degradation. A speciﬁc siR-
NA against TRAF6 decreased by >60% its expression and partially
prevented IKKb degradation induced by IL-1b (Fig. 4). Knocking-down transforming growth factor (TGF)-b-activated kinase 1
(TAK1), the kinase recruited by TRAF6 for the activation of IKK
complex [14,29], was not as efﬁcient as observed for TRAF6 (less
than 30%), but this was sufﬁcient to partially prevent IKKb degra-
dation induced by IL-1b (Fig. 4). Beside IKK activation, TRAF6 also
induces Jun-N-terminal Kinase (JNK) via TAK1 [29,30]; in line with
this, TRAF6 and TAK1 KD decreased JNK activation (Fig. 4). Of note,
IL-1b induced higher activation of JNK than TNF-a in b-cells
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started already at 5 min of treatment, with further increase by
10 min (Supplementary Fig. 5S B and C). To determine if JNK acti-Fig. 3. IKKb degradation following inhibition of different components of the IKK
complex. INS-1E cells were transfected with siRNAs speciﬁc for IKKa, IKKb or IKKc
subunits, or a control siRNA (siCT). Three days after transfection cells were treated
either with IL-1b or TNF-a (as indicated in the ﬁgure) for 30 min. Western blots for
IKKa, IKKb, IKKc and tubulin were then performed. (A): representative ﬁgure of 5–8
independent experiments. (B): quantiﬁcation of the results. ⁄P 6 0.05 cells trans-
fected with siIKK vs. siCT under the same treatment conditions.
Fig. 4. Involvement of TRAF6, TAK1 and JNK activation in IL-1b-induced IKKb
degradation in b-cells. INS-1E cells were transfected with siRNA speciﬁc for TRAF6
(siTRAF6) and TAK1 (siTAK1), or a control siRNA (siCT). Three days after transfection
the cells were pre-treated or not with the JNK inhibitor (SP600125) and then left
untreated (control) or treated with IL-1b for 30 min, as indicated in the ﬁgure.
Western blots for IKKb, P-JNK and tubulin were then performed. (A): representative
ﬁgure of 4–8 independent experiments is shown. (B): quantiﬁcation of the results.
Data are means ± SEM of 4–8 experiments. ⁄P 6 0.05 cells transfected with siCT vs.
siTRAF6 or TAK1 with similar treatment. §P 6 0.005 IL-1b treated cells vs IL-1b + JNK
inhibitor transfected with the same siRNA.vation plays a role in IKKb degradation, we used the JNK inhibitor
SP600125 (SP). SP inhibited JNK activation by P80%, as measured
by its phosphorylation. JNK inhibition partially prevented IL-1b-in-
duced IKKb degradation (Fig. 4), an effect similar to the one ob-
served with a combination of TAK1 KD and JNK inhibition. This
suggests that these two proteins are part of the same signalling
pathway involved in IKKb degradation. Use of a second set of siR-
NAs conﬁrmed the observations described above (data not shown).
4. Discussion
The main ﬁndings of the present study, taken together with our
previous observations [5,7], are summarized in Fig. 5. We have pre-
viously shown that IL-1b induces an earlier and stronger activation
of ERK and of the IKK complex, as compared to TNF-a, leading to a
more intense and protracted NF-jB activation and consequent
expression of downstream genes involved in b-cell dysfunction
and death. Furthermore, IL-1b, but not TNF-a, alone induce INS-
1E cell dead [7]. We presently show that there is a differential
usage of IKK complexes following b-cell exposure to IL-1b or
TNF-a. IL-1b induces degradation of IKKb via the proteasome, lead-
ing to a preferential use of IKK complexes containing only the IKKa
subunit. This degradation is dependent, at least in part, on the
presence of the IKKc subunit and activation of the TRAF6 signalling
pathway (Fig. 5). Of note, TRAF6 is involved in the activation of
NF-jB by IL-1b but not by TNF-a [14,17], which may contribute
to the different effects of the two cytokines on IKK. Activation of
JNK via TAK1 is also important for IL-1b-induced IKKb degradation,
suggesting a new effect of this kinase, previously shown to contrib-
ute for cytokine-induced b-cell apoptosis [10,31].
The IKKb subunit was described as indispensable for NF-jB acti-
vation by different pro-inﬂammatory cytokines [32,33]. Due to the
importance of NF-jB activation in auto-immune diseases [33],
such as T1D, many ‘‘speciﬁc’’ inhibitors for IKK complexes possess-
ing the IKKb subunit were developed [27,33]. Recently, however, it
was shown that while TNF-a-induced NF-jB activation is indeedFig. 5. Proposed model for the differential IKK activation by IL-1b and TNF-a in b-
cells. In red are the proteins putatively involved in IKKb degradation induced by IL-
1b.
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[20]. The heterodimers of IKKa and IKKb, in association with IKKc,
are the most common IKK complexes observed in cells containing
the three isoforms [14,17,34]. We presently describe, however,
that b-cells treated with IL-1b have preferentially IKKa homodi-
mers in association with IKKc (Fig. 2A). This is probably secondary
to IL-1b-induced IKKb degradation. This effect seems to be speciﬁc
for b-cells, in which NF-jB activation is pro-apoptotic, since it is
not observed in rat ﬁbroblasts (Supplementary Fig. 3S A). Of note,
NF-jB activation in rat ﬁbroblasts is anti-apoptotic, and TNF-a
induces stronger activation of this transcription factor as compared
to IL-1b [5], emphasizing the context- and cell-dependent regula-
tion of NF-jB and downstream genes.
IKKa and IKKb share high structural similarity, but they play
different roles in the regulation of NF-jB translocation to the nu-
cleus [17] and its post-translational modulation [16]. IKKa regu-
lates both NF-jB transcriptional activity and the regulation of
transcriptional co-activators, co-repressors and histones [35–40].
On the other hand, IKKb contains an ubiquitin-like domain which
seems to be important for its activation and degradation [41]. In
fact, IKKb degradation may be an important mechanism to attenu-
ate NF-jB activation in other cell types, and disruption of this
mechanism favors neoplasias [42]. Thus, the presently observed
preferential usage of IKK complexes containing only the IKKa sub-
unit following IL-1b exposure might contribute to the more intense
NF-jB activation and expression of downstream genes observed in
b-cells [5,7]. Of note, we have previously shown that neither IL-1b
nor TNF-a induce the non-canonical (IKKa-dependent) NF-jB
pathway [7].
Our data suggest that IKKb degradation requires the presence of
IKKc. IKKc has no kinase activity, but it allows association between
the IKK complex and regulatory proteins that modulate IKK activa-
tion/repression [14,28]. Additional experiments are required to
clarify how IKKc contributes for the presently observed IL-1b-in-
duced IKKb degradation.
Different pro-inﬂammatory cytokines may contribute to insuli-
tis and b-cell apoptosis during development of T1D [1,43]. We
presently show that IL-1b and TNF-a utilize different ‘‘strategies’’
for NF-jB activation in pancreatic b-cells, including usage of differ-
ent members of the IKK complex. Since NF-jB is a key transcription
factor for insulitis and apoptosis [1,44], this novel information
open interesting possibilities for a context-dependent modulation
of the transcription factor to protect b-cells in early T1D.
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